JAMA. 1988 Jul 1;260(1):37-41. doi: 10.1001/jama.1988.03410010045032.
The progression of retinopathy was reevaluated at two years in 64 of the 68 patients with mild to moderate diabetic retinopathy, originally randomly assigned for an eight-month period either to intensified diabetic control with continuous subcutaneous insulin infusion (CSII) or to unchanged conventional injection treatment. Twenty-three of the 34 patients in the former group and 24 of the 34 in the latter agreed to continue to follow their original treatment assignment for a further 16 months. The others crossed over at the end of the first eight months of the study. During those first eight months, substantial lowering of blood glucose concentration had been achieved in the CSII group, unexpectedly associated with evidence of accelerated progression of retinopathy compared with the conventional injection treatment group. Glycemic separation was maintained at two years between the two groups continuing to receive the assigned treatment; during this time the mean retinopathy level deteriorated with conventional injection treatment and improved with CSII. At two years the degree of retinopathy in the two treatment groups was indistinguishable, with some trend to lesser overall deterioration with CSII. It is concluded that, in diabetics with mild to moderate nonproliferative retinopathy, the acceleration in activity associated with tightened control is not sustained and does not initiate vasoproliferative deterioration in retinopathy.
68例轻度至中度糖尿病视网膜病变患者最初被随机分配接受为期8个月的持续皮下胰岛素输注强化糖尿病控制(CSII)或不变的传统注射治疗,其中64例在两年时对视网膜病变进展进行了重新评估。前一组34例患者中有23例,后一组34例患者中有24例同意继续遵循其原来的治疗分配方案再持续16个月。其他人在研究的前8个月末进行了交叉。在最初的8个月期间,CSII组血糖浓度大幅降低,出乎意料的是,与传统注射治疗组相比,有视网膜病变加速进展的证据。继续接受指定治疗的两组之间在两年时维持了血糖差异;在此期间,传统注射治疗使平均视网膜病变水平恶化,而CSII使其改善。两年时,两个治疗组的视网膜病变程度无明显差异,CSII组总体恶化程度有稍低的趋势。结论是,在轻度至中度非增殖性视网膜病变的糖尿病患者中,与强化控制相关的活动加速不会持续,也不会引发视网膜病变的血管增殖性恶化。